S Ahmed1; E Underwood1; S Gray1; K Peters1; H Mak1; A Edwards1;
1 AstraZeneca, UK
AbstractDiscovery Sciences at AstraZeneca is responsible for identifying molecules active against novel targets in a range of therapeutic areas. For most drug discovery projects in this early phase it is integral to have high quality recombinant protein to drive screening and lead optimisation activities.Our platform and processes for recombinant protein production at AZ are comprised of a number of stages: Construct design and molecular biology, protein expression, protein purification and quality control. We are constantly looking for ways to increase throughput and streamline our methods toimprove efficiency as we support an increasingly complex project portfolio and are stretched to reduce timelines.